Gadsbøll Niels, Pedersen Christian Torp
Medicinsk Afdeling, Køge Sygehus, Lykkebækvej 1, 4600 Køge, Denmark.
Ugeskr Laeger. 2013 May 27;175(22):1566-8.
A new Cochrane metaanalysis has reviewed the literature on the use of angiotensin receptor blockers (ARB) in patients with heart failure and left ventricular systolic dysfunction. The conclusion supports the present recommendation from the European Society of Cardiology that angiotensin converting enzyme inhibitors (ACE-I) are first choice and that ARBs should be reserved to patients who are intolerant to ACE-Is. Neither ACE-Is nor ARBs are effective in the treatment of heart failure patients with normal left ventricular function.
一项新的Cochrane系统评价回顾了关于血管紧张素受体阻滞剂（ARB）用于心力衰竭和左心室收缩功能障碍患者的文献。该结论支持欧洲心脏病学会目前的建议，即血管紧张素转换酶抑制剂（ACE-I）是首选，而ARB应保留用于不能耐受ACE-I的患者。ACE-I和ARB对左心室功能正常的心力衰竭患者均无效。
